Clinical Trial Update: A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing HB1801 to Taxotere in locally advanced or metastatic non-small cell lung cancer; status is currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HB1801
• Taxotere (docetaxel)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN